Navigation Links
Norgine and Innovacell Enter Into an Exclusive Licensing Agreement for ICEF15 - An Innovative Personalised Cell Therapy to Treat Faecal Incontinence
Date:12/17/2013

LONDON, December 17, 2013 /PRNewswire/ --

Norgine B.V. ("Norgine") and Innovacell today announced they have entered into an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15. Innovacell and Norgine will co-develop ICEF15 and Norgine will commercialise the product. The start of the ICEF15 phase IIb clinical trial is imminent and it is anticipated that the first patient will be dosed in Q1 2014.

     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a)

     (Photo: http://photos.prnewswire.com/prnh/20131213/659040 )

ICEF15 is developed for both men and women suffering from faecal incontinence with sphincter weakness or damage. ICEF15 is a personalised cell-based product concept based upon proliferating autologous myoblasts from a biopsy taken from the patients' own muscle. The patient's proliferated muscle cells are re-injected into the patient's external anal sphincter muscle, using Innovacell's proprietary injection device, thereby regenerating the muscle´s full functionality.

Phase I/II clinical trial data have shown a rapid reduction in the symptoms of faecal incontinence as well as an improvement in the quality of life. In addition, data from a retrospective study (5 years - post treatment) show that ICEF15 has a lasting effect.

It is estimated that in major European countries, around 5 per cent of all adult men and women will suffer from faecal incontinence.

Ekkehart Steinhuber, CEO at Innovacell, said, "By partnering with Norgine, Innovacell is accessing demonstrated gastroenterology and commercial expertise and capabilities that will accelerate development and market entry of ICEF15 in Europe, SADAC and MENA. ICEF15 could help many patients to overcome faecal incontinence, a very debilitating condition, and regain their quality of life."

Peter Stein, CEO at Norgine, said, "Our collaboration with Innovacell is a major step forward in developing a truly innovative therapy in a disease area in which we have strong expertise.  Faecal incontinence is a common and distressing condition that may severely restrict patients' activities and through the development and marketing of ICEF15, we hope to offer a novel and long life lasting treatment option."

He added: "ICEF15 is a strong addition to our portfolio. Our approach to partnering is flexible and our efforts are always focused to find and work with partners who have complementary skills and a shared vision for improving healthcare. Partnering is a key priority for our long-term growth and success as an independent and leading pan-European specialty pharmaceutical company."

Financial terms are not disclosed.

Access full release http://www.norgine.com

Media Contacts

Isabelle Jouin, Norgine, Tel: +44(0)1895-453-643;  M: + 44(0)771-406-1327

Christian Loitz, wikopreventk GmbH; christian.loitz@wikopreventk.com; M : +43(0)650-7245825



'/>"/>
SOURCE Norgine B.V.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
3. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
4. Elsevier Appoints New President of Elsevier CPM Resource Center
5. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
6. Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
7. Guangzhous Sun Yat-sen University Cancer Center Debuts MOSAIQ in the Chinese Platform
8. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
9. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
10. Childrens National Medical Center Breaks MRI Speed Sound Barrier
11. Pernix Therapeutics Introduces Omeclamox-Pak®, First Product in Gastroenterology Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... -- According to a study conducted by Persistence Market ... a CAGR of 6.5% during the forecast period 2016-2024. According to ... be the leading market for cryotherapy globally during the forecast period  ... Highlights from the ... and adequate supply of gas in order to provide smoother maintenance ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... -- Pfizer joins Astex, AstraZeneca, GlaxoSmithKline, ...   Major research investment to work ...   The Milner Therapeutics Institute today announces ... partner to the Milner Therapeutics Consortium. Pfizer has agreed ... of materials between industry and academia and allocation of ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based ... recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting from ... large range of supplements that keep the body functioning at its peak performance ...
(Date:1/20/2017)... ... 20, 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions ... said Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique ... Mystique lens flare and light leak transitions have a very high-dynamic range for super ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Angel”: ... the Lord has set out for each of his children. “The Angel” is the ... School of Music in New York City, and impassioned writer. , When asked of ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton Healthcare Products ... was featured in a study indicating superior performance against competitive products in secretion ... Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: a moving and ... God’s Lighthouse” is the creation of published author, Gene Gaapf, a retired truck driver, ... , “I have been writing since high school and have many different titles,” Gaapf ...
Breaking Medicine News(10 mins):